• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

对 RAF 抑制剂 PLX4720 诱导的细胞凋亡具有抗性的 B-RAFV600E 黑色素瘤细胞中 MEK 非依赖性存活。

MEK-independent survival of B-RAFV600E melanoma cells selected for resistance to apoptosis induced by the RAF inhibitor PLX4720.

机构信息

Immunology and Oncology Unit, Newcastle, New South Wales, Australia.

出版信息

Clin Cancer Res. 2011 Feb 15;17(4):721-30. doi: 10.1158/1078-0432.CCR-10-2225. Epub 2010 Nov 18.

DOI:10.1158/1078-0432.CCR-10-2225
PMID:21088259
Abstract

PURPOSE

To examine mechanisms that determine long-term responses of B-RAF(V600E) melanoma cells to B-RAF inhibitors.

EXPERIMENTAL DESIGN

B-RAF(V600E) melanoma cells were exposed to the B-RAF inhibitor PLX4720 for prolonged periods to select for cells resistant to apoptosis induced by the inhibitor. The resultant cells were analyzed for activation of extracellular signal regulated kinase (ERK), MAP/ERK kinase (MEK), and Akt, and related signals. Their roles in survival of the cells were also examined.

RESULTS

B-RAF(V600E) melanoma cells selected for resistant to PLX4720-induced apoptosis retained the V600E mutation in B-RAF, and proliferated steadily in the presence of the inhibitor, albeit with slow growth rate. These cells displayed high levels of ERK activation, that is, at least in part, independent of the conventional RAF/MEK/ERK pathway, as MEK activation was low and inhibition of MEK did not significantly block activation of ERK. In contrast, extracellular signals appeared involved. This was associated with elevated activation of the phosphoinositide 3-kinase (PI3k)/Akt pathway and could be inhibited by serum starvation and inhibition of PI3k/Akt. Inhibition of MEK did not impact on survival of these cells, whereas serum starvation, inhibition of PI3K/Akt, and inhibition of ERK1/2 reduced their viability.

CONCLUSIONS

These results indicate that sensitivity to induction of apoptosis may be a major determinant of long-term responses of B-RAF(V600E) melanomas to specific inhibitors and suggest that rebound melanoma growth after initial treatment with the inhibitors may not be responsive to MEK inhibitors, but may be susceptible to inhibition of the PI3k/Akt pathway.

摘要

目的

研究决定 B-RAF(V600E) 黑色素瘤细胞对 B-RAF 抑制剂长期反应的机制。

实验设计

将 B-RAF(V600E) 黑色素瘤细胞长时间暴露于 B-RAF 抑制剂 PLX4720 中,以选择对抑制剂诱导的细胞凋亡有抗性的细胞。分析所得细胞中细胞外信号调节激酶 (ERK)、MAP/ERK 激酶 (MEK) 和 Akt 的激活情况及其相关信号。还研究了它们在细胞存活中的作用。

结果

选择对 PLX4720 诱导的细胞凋亡具有抗性的 B-RAF(V600E) 黑色素瘤细胞保留了 B-RAF 的 V600E 突变,并且尽管生长速度缓慢,但在抑制剂存在下仍稳定增殖。这些细胞表现出高水平的 ERK 激活,即至少部分独立于传统的 RAF/MEK/ERK 途径,因为 MEK 激活较低,抑制 MEK 并不能显著阻断 ERK 的激活。相比之下,细胞外信号似乎参与其中。这与磷酸肌醇 3-激酶 (PI3k)/Akt 途径的激活升高有关,可通过血清饥饿和 PI3k/Akt 抑制来抑制。抑制 MEK 对这些细胞的存活没有影响,而血清饥饿、PI3K/Akt 抑制和 ERK1/2 抑制降低了它们的活力。

结论

这些结果表明,对凋亡诱导的敏感性可能是 B-RAF(V600E) 黑色素瘤对特定抑制剂的长期反应的主要决定因素,并表明抑制剂初始治疗后黑色素瘤的反弹生长可能对 MEK 抑制剂无反应,但可能对 PI3k/Akt 途径的抑制敏感。

相似文献

1
MEK-independent survival of B-RAFV600E melanoma cells selected for resistance to apoptosis induced by the RAF inhibitor PLX4720.对 RAF 抑制剂 PLX4720 诱导的细胞凋亡具有抗性的 B-RAFV600E 黑色素瘤细胞中 MEK 非依赖性存活。
Clin Cancer Res. 2011 Feb 15;17(4):721-30. doi: 10.1158/1078-0432.CCR-10-2225. Epub 2010 Nov 18.
2
Combinatorial treatments that overcome PDGFRβ-driven resistance of melanoma cells to V600EB-RAF inhibition.联合治疗方案可克服黑色素瘤细胞对 V600EB-RAF 抑制的 PDGFRβ 驱动耐药性。
Cancer Res. 2011 Aug 1;71(15):5067-74. doi: 10.1158/0008-5472.CAN-11-0140.
3
[Synergistic effect of targeted inhibition of MEK/ERK and PI3K/AKT survival signaling pathways on induction of apoptosis in melanoma].[MEK/ERK和PI3K/AKT生存信号通路的靶向抑制对黑色素瘤细胞凋亡诱导的协同作用]
Sichuan Da Xue Xue Bao Yi Xue Ban. 2014 May;45(3):355-61.
4
Signal transduction of MEK/ERK and PI3K/Akt activation by hypoxia/reoxygenation in renal epithelial cells.肾上皮细胞中缺氧/复氧对MEK/ERK和PI3K/Akt激活的信号转导
Eur J Cell Biol. 2006 Nov;85(11):1189-99. doi: 10.1016/j.ejcb.2006.06.001. Epub 2006 Jul 24.
5
Inhibition of either phosphatidylinositol 3-kinase/Akt or the mitogen/extracellular-regulated kinase, MEK/ERK, signaling pathways suppress growth of breast cancer cell lines, but MEK/ERK signaling is critical for cell survival.抑制磷脂酰肌醇3-激酶/蛋白激酶B(PI3K/Akt)信号通路或丝裂原/细胞外调节激酶(MEK/ERK)信号通路,均可抑制乳腺癌细胞系的生长,但MEK/ERK信号通路对细胞存活至关重要。
Breast Cancer Res Treat. 2005 Sep;93(2):177-88. doi: 10.1007/s10549-005-4794-6.
6
Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy.抑制磷脂酰肌醇3-激酶/蛋白激酶B/雷帕霉素哺乳动物靶标信号通路而非丝裂原活化蛋白激酶/细胞外信号调节激酶信号通路,可减弱层粘连蛋白介导的小细胞肺癌细胞存活以及对甲磺酸伊马替尼或化疗的耐药性。
Cancer Res. 2005 Sep 15;65(18):8423-32. doi: 10.1158/0008-5472.CAN-05-0058.
7
Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.RAF/MEK/ERK和PI3K/PTEN/AKT信号通路在恶性转化和耐药中的作用。
Adv Enzyme Regul. 2006;46:249-79. doi: 10.1016/j.advenzreg.2006.01.004. Epub 2006 Jul 18.
8
Synthetic lethal interaction between PI3K/Akt/mTOR and Ras/MEK/ERK pathway inhibition in rhabdomyosarcoma.横纹肌肉瘤中 PI3K/Akt/mTOR 和 Ras/MEK/ERK 通路抑制的合成致死相互作用。
Cancer Lett. 2013 Sep 1;337(2):200-9. doi: 10.1016/j.canlet.2013.05.010. Epub 2013 May 16.
9
Inhibition of B-Raf/MEK/ERK signaling suppresses DR5 expression and impairs response of cancer cells to DR5-mediated apoptosis and T cell-induced killing.抑制B-Raf/MEK/ERK信号传导可抑制DR5表达,并削弱癌细胞对DR5介导的凋亡和T细胞诱导杀伤的反应。
Oncogene. 2016 Jan 28;35(4):459-67. doi: 10.1038/onc.2015.97. Epub 2015 Apr 13.
10
The PI3K/Akt and mTOR/P70S6K signaling pathways in human uveal melanoma cells: interaction with B-Raf/ERK.人眼葡萄膜黑色素瘤细胞中的 PI3K/Akt 和 mTOR/P70S6K 信号通路:与 B-Raf/ERK 的相互作用。
Invest Ophthalmol Vis Sci. 2010 Jan;51(1):421-9. doi: 10.1167/iovs.09-3974. Epub 2009 Aug 6.

引用本文的文献

1
Overcoming Vemurafenib Resistance in Metastatic Melanoma: Targeting Integrins to Improve Treatment Efficacy.克服转移性黑色素瘤中的维莫非尼耐药性:靶向整合素以提高治疗效果。
Int J Mol Sci. 2024 Jul 20;25(14):7946. doi: 10.3390/ijms25147946.
2
Evodiamine inhibits growth of vemurafenib drug-resistant melanoma via suppressing IRS4/PI3K/AKT signaling pathway.吴茱萸碱通过抑制 IRS4/PI3K/AKT 信号通路抑制维莫非尼耐药黑色素瘤的生长。
J Nat Med. 2024 Mar;78(2):342-354. doi: 10.1007/s11418-023-01769-9. Epub 2024 Feb 7.
3
Molecular Targeting of the BRAF Proto-Oncogene/Mitogen-Activated Protein Kinase (MAPK) Pathway across Cancers.
跨癌症的BRAF原癌基因/丝裂原活化蛋白激酶(MAPK)通路的分子靶向治疗
Int J Mol Sci. 2024 Jan 3;25(1):624. doi: 10.3390/ijms25010624.
4
Current understanding of epigenetics role in melanoma treatment and resistance.目前对表观遗传学在黑色素瘤治疗及耐药性中的作用的理解。
Cancer Cell Int. 2022 Oct 12;22(1):313. doi: 10.1186/s12935-022-02738-0.
5
Efficacy of rigosertib, a small molecular RAS signaling disrupter for the treatment of -mutant colorectal cancer.瑞戈非尼(一种小分子RAS信号传导破坏剂)治疗KRAS突变型结直肠癌的疗效。
Cancer Biol Med. 2021 Aug 4;19(2):213-28. doi: 10.20892/j.issn.2095-3941.2020.0532.
6
Deregulated FASN Expression in BRAF Inhibitor-Resistant Melanoma Cells Unveils New Targets for Drug Combinations.BRAF抑制剂耐药黑色素瘤细胞中脂肪酸合酶(FASN)表达失调揭示了联合用药的新靶点。
Cancers (Basel). 2021 May 10;13(9):2284. doi: 10.3390/cancers13092284.
7
High Yap and Mll1 promote a persistent regenerative cell state induced by Notch signaling and loss of p53.High Yap 和 Mll1 通过 Notch 信号诱导和 p53 缺失促进持久的再生细胞状态。
Proc Natl Acad Sci U S A. 2021 Jun 1;118(22). doi: 10.1073/pnas.2019699118.
8
The "ART" of Epigenetics in Melanoma: From histone "Alterations, to Resistance and Therapies".黑色素瘤表观遗传学的“ART”:从组蛋白“改变到耐药和治疗”。
Theranostics. 2020 Jan 1;10(4):1777-1797. doi: 10.7150/thno.36218. eCollection 2020.
9
Dissecting Mechanisms of Melanoma Resistance to BRAF and MEK Inhibitors Revealed Genetic and Non-Genetic Patient- and Drug-Specific Alterations and Remarkable Phenotypic Plasticity.解析黑色素瘤对 BRAF 和 MEK 抑制剂耐药的机制揭示了遗传和非遗传的患者和药物特异性改变以及显著的表型可塑性。
Cells. 2020 Jan 7;9(1):142. doi: 10.3390/cells9010142.
10
KSRP modulates melanoma growth and efficacy of vemurafenib.KSRP 调节黑色素瘤的生长和威罗菲尼的疗效。
Biochim Biophys Acta Gene Regul Mech. 2019 Aug;1862(8):759-770. doi: 10.1016/j.bbagrm.2019.06.005. Epub 2019 Jun 30.